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Abstract: This study provides an insight into the effects of absence of legal regulation on clinical trials; on 
acceptance and success of immunization programs in developing countries. The purpose of this research is to 
identify the effect of absence of legal regulatory framework for clinical trials on humans; on acceptance and success 
of immunization programs in developing countries. Since the findings of this work show that lack of well-
functioning legal and regulatory framework for clinical trials in developing countries contributes to the rejection of 
immunization as a result of fear about the quality and safety of vaccines used, establishing regulatory agencies with 
powers and facilities that would enable it ensure the quality, safety and efficacy of vaccines used in immunization is 
a most if the trust and confidence of people of developing countries in immunization is to be obtained. 
 





Immunization has been considered as one of 
the most efficient and most effective of all 
health interventions.1 It contributes in 
preventing devastating sicknesses and 
deformities. It helps in saving millions of lives 
every year, and improves the lives of children 
for a better future.2 
 Despite all the above credit of immunization 
however, some people do not consider it as 
worthy of any praise. In fact, some consider 
vaccination as something dangerous to health 
and therefore reject it for fear of lack of its 
safety.3 The global immunization programs set 
the goal of saving an estimated 2.5 million 
children from death every year. But as a result 
of its rejection by the targeted population and 
other barriers, millions of children in 
developing countries could not get access to 
complete dose of vaccines as scheduled for 
their intake.4 
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  The advocates of vaccination always 
dispense with the reasons given by its 
antagonists for their fear of its safety as 
baseless and merely built on illiteracy, 
religious, traditional or political sentiment, 
which cannot be scientifically proven.5 But 
instead of regarding the fear of people about 
vaccine safety as a baseless ground for its 
rejection, investigation should be made to 
verify the basis for their claim and if the 
investigation finds merit in the claim, then a 
necessary action should be taken to ensure the 
safety of the vaccines used in immunization. 
This would make the people feel that their 
demands are being attended by the relevant 
stakeholders in immunization program, and 
would make them have trust and confidence in 
the program and its providers. 
 The current incidents of vaccinating 
children with unsafe and unapproved vaccines 
used for illegal and unethical clinical trials in 
Nigeria6 and India,7 which caused the death and 
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incapacitation of many of them, provide a 
great concern about the issue. These and 
similar cases provide a warning signal to 
developing countries that unless they provide 
legal regulatory framework for drug and 
clinical trials on humans in their countries, the 
international pharmaceutical companies and 
other clinical research institutes may continue 
to take the countries as their laboratories for 
their clinical trials and to use immunization 
programs as a means of obtaining their 
subjects for experiments. This will, of course, 
continue to make people reject immunization 
programs for the fear of their safety. 
 
1. Why the Fear of Lack of Quality 
and Safety of Vaccines? 
 
There are three main reasons why people 
reject vaccination, namely: 
a) Fear about quality and safety of 
vaccines; 
b) Misconceptions and myth; and 




                                                                                                  
Informed Consent; Law School Student Scholarship, 
Paper 544, (2014), p 19 
7 Sorojini, N. and Deepa, V., Trials and 
Tribulations: An Expose of the HPV vaccine Trials by 
the 72nd Parliamentary 
Standing Committee II Reports, Indian Journal of 
Medical Ethics, (2013), Vol 10, No. 4, pp. 220-223 
8 Schoub, B., Vaccination and the Anti-
vaccinationists; National Institute of 
Communicable Diseases, 
http://www.nicd.ac.za/pubs/press/vaccination.h
tm. Accessed 16th April, 2016 
  One of the most difficult challenges 
faced by the United Nations in its 
immunization campaign is on how to convince 
the people, to whom the program is directed, 
that the vaccination is for their own best 
interest. After sourcing fund for research and 
production of vaccines by the World Health 
Organization, the UNICEF and other donors, 
nothing is more challenging than that the 
people who are meant to benefit from it reject 
its distribution and deny its usefulness.9 But 
why do people reject something provided for 
them for their own good, which if they are 
allowed to provide for themselves, many 
cannot afford to get? 
 The World Health Organization began 
to trace the basis for fears of people about 
vaccines and immunizations. At the end, the 
WHO provided a list of six common grounds 
which people give as their reasons for fear and 
rejection: 
1) With better hygiene and satisfaction, 
diseases have begun to disappear naturally. 
2) Vaccine-preventive diseases have 
been virtually eradicated from a given 
(source) country, and therefore, no need any 
longer to receive it. 
3) People who get diseases are the ones 
who have been vaccinated. 
4) Some vaccines can cause death and it 
is safe not to get vaccinated. 
5) Some vaccines can cause harmful side 
effects, sicknesses and long-term unforeseen 
effects. 
6) Multiple vaccinations for different 
diseases administered to a child may increase 
the tendency of manifesting serious side 
effects.10 
 A careful study of the above common 
grounds would reveal that generally, the 
reasons given by those who reject 
immunization revolve around the fear of 
quality, safety and efficiency of vaccinations. 
Many writers and commentators attribute the 
reasons given by the hesitant parents and 
vaccine refuser’s for their fear of lack of safety 
in vaccination and immunization as mere 
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flimsy, built on illiteracy,11 religious, political, 
traditional or individual sentiments.12 But an 
opposing view is that the hesitant parents’ 
and refusers’ reasons should be verified 
rather than ignored. This is because, their 
reasons may be genuine, and addressing it 
would help in resolving the problem of 
rejecting vaccination and immunization. 
Thus, a UK based social researcher 
commented on the rejection of immunization 
by some states in Northern Nigeria between 
2002 to 2003: 
 
“Well the fact that the Nigerian people are 
afraid in the first instance means that something 
is wrong somewhere. If they have fears, then 
someone is not doing their job properly. 
Therefore, these fears must be investigated.”13 
In the same vein, another commentator 
opined: 
“I believe that it is a responsibility of 
government and opinion leaders within society, 
to bring into question; the safety of the vaccines. 
Perhaps, if international bodies like WHO had 
followed the right procedures for involving 
communities and explaining things properly, 
then people would not be so suspicious. After all, 
democracy is about participation, and to 
participate, one has to ask. No?”14 
The above line of opinions can be justified. It 
is only when a people’s grievances against a 
programme or policy are attended to, and 
addressed accordingly that may make them to 
accept such a programme or policy as legitimate, 
and to build their trust and confidence in it. It is 
not surprising that the current laws and 
regulatory framework for immunizations in the 
United States are direct response to public health 
crises caused by unsafe vaccines in the 20th 
century. The U.S government’s first attempt to 
regulate and control the safety and quality of all 
biological drugs was as a result of the 
contaminated smallpox vaccines produced in St 
Louis, which resulted to the death of nine 
children.15 Thus, in 1902, the Biologics Control 
Act was enacted into law. 
Where the issue of safety or otherwise of 
vaccines is the basis for rejection of 
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immunization by a people, then the best questions 
to be addressed are; 
i. Are there such unsafe vaccines that 
could be smuggled into an immunization 
programme? 
ii. If there are, what can we do to prevent 
their administration in immunization and 
vaccination programmes, and to ensure the 
targeted people that only quality and safe vaccines 
are used for immunization, so that we retain their 
trust and confidence in immunization? 
 
 
A lot have been written in proof of safety, 
quality and efficacy of vaccines and vaccination.16 
However, where the international immunization 
and vaccination quality and safety standards are 
compromised, the long acclaimed safety and 
effectiveness would no longer be assured.17 In 
such circumstances, unsafe and contaminated 
vaccines could be smuggled into a country and 
used in immunization programme. Apart from 
that, manufacturers of vaccines and research 
institutes may use the avenue to test the safety 
and efficacy of a new drug, using some of the 
participants as their clinical subjects without their 
consent, thereby exposing them to an 
unprecedented medical risk. 
Currently, international pharmaceutical 
companies from the developed nations find it 
more lucrative to conduct their clinical trials in 
developing countries, where there are low cost of 
production and lack of functional legal regulatory 
framework for the conduct of clinical trials.18 
Governments of these countries sometimes see 
the trials as a means of providing medical care, 
which otherwise, would have been unaffordable.19 
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There are records of illegal and unethical 
clinical trials and experimentation on human 
subjects with new drugs/vaccines, some of which 
were employed in immunization process, mostly 
conducted in developing countries, and which 
have resulted in the unsuspected victims of the 
trials either loss their lives or became 
incapacitated. These, of course, are some of the 
genuine reasons that erode some of the people’s 
(including the enlightened among them)20 trust 
and confidence in immunization, and make them 
hesitate or refuse to patronize it all together. The 
following are examples of cases of illegal and 
unethical trials through immunization 
programmes. 
 
3.1 The Cutter Polio Crisis of the U.S 
 
About 200,000 American children were 
vaccinated in 1955, against polio meningitis. The 
vaccine was found to be defective, as it contained 
active poliovirus.21 Cutter laboratories, the 
manufacturers of the vaccine were found liable 
for causing 40,000 polio infection cases. 10 
vaccinated children were reported to have died 
and 200 suffered paralysis.22 The vaccine was 
banned, and to prevent future occurrence, the 
U.S’ government established the Division of 
Biologics Standards, which is the predecessor of 
the present Centre for Biologics Evaluation and 
Research (BER), a unit under the Food and Drugs 
Administration (FDA), and saddled with the 
responsibility of regulating and inspecting 
vaccine manufacturing processes, so as to ensure 
safety and efficacy of vaccine.23 
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3.2 The 1996 Pfizer’s Trovan Trials in Nigeria 
 
In 1996, there was an outbreak of polio 
meningitis in Kano state of Nigeria. The U.S based 
Pfizer pharmaceutical company dispatched a 
medical team to Kano, to participate in the polio 
vaccination exercise in the area, and to test its new 
developed Trovafloxacin antibiotic drugs on 
Nigerian children. Two hundred children were 
selected for the trial. They were made to sign 
consent form which they could not read nor 
understand24. They were administered the drug 
without obtaining their parents’ informed consent 
as well. The children were not informed that they 
were undergoing an experimental test of the drug. 
There was no approval of the trial by an ethical 
review committee.25 Eleven out of the total selected 
number of the children died after the trial (5 
received trovafloxacin and 6 ceftriaxone).26 Several 
other children were rendered deaf, blind, paralyzed 
or mentally incapacitated.27 
 
3.3 The 2009 HPV Vaccine Trials in India 
 
India has been currently a chosen place for 
clinical trials by many pharmaceutical companies. 
The country’s large population, the low cost for 
conducting the trials28 together with lesser 
restrictions in conducting clinical trials give 
attraction for multinational pharmaceutical 
companies.29 
In 2009, some 23,000 school girls, between the 
ages of 10-14 were enrolled into Human Papilloma 
Virus (HPV) vaccine trials, called ‘Demonstration 
Projects’ for the prevention of cervical cancer. The 
trials were conducted by the Program for 
Appropriate Technology in Health (PATH), a U.S 
based NGO, in Khammam district of Andhra 
Pradesh State, and Vadodara district of Gujarat. 
PATH conducted the trials in collaboration of the 
governments of the two States and the Indian 
Council of Medical Research (ICMR)30. The vaccines 
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were ‘Gardasil’, manufactured by Merck Sharp & 
Dohme (MSD), and ‘Cervarix’, manufactured by 
GlaxoSmithKline.31 The girls were administered 
the vaccines and some months later, many of them 
fell sick. In 2010, five of the girls died in Andhra 
Pradesh and two in Gujarat, while about 1,200 
were reported to have suffered from serious side 
effect and needed continuing medical attention.32 
Even though the death of the seven girls was 
summarily dismissed as unrelated to the trials 
without any in-depth investigation,33 the 72nd 
Parliamentary Report stated that what PATH did 
was a clear breach of trust and violation of the 
human rights of the girls and a serious breach of 
medical ethics.34 The ‘projects’, which were 
intended earlier to be integrated into National 
Indian Immunization Programme were suspended 
by the Ministry of Health in 2010.35 
 
2. Regulation of Clinical Trials: A 
Step Towards Building Public Trust and 
Confidence in Immunization 
 
The national governments of the developing 
countries, the WHO, UNICEF and other bodies 
participating in the global immunization 
programmes may be faced with difficulty in 
convincing people to accept vaccines,36 due to the 
lack of public trust and confidence in the safety 
and efficacy of the vaccines, lack of confidence in 
the immunization policy-makers, and the motives 
of the vaccine donors or providers.37 The reason 
for this may be past negative experiences with 
vaccines, with the providers, or with the policy-
makers.38 Another reason may be the accessibility 
of information about negative effects of 
vaccination in one locality, like the three case 
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studies mentioned above. 
Where exists public trust and confidence crisis 
about vaccination or immunization, it becomes the 
responsibility of the stakeholders to find out ways 
of winning back the trust and confidence of the 
public about immunization and the safety and 
efficacy of vaccines, for without public trust and 
confidence, even the best science and public health 
strategies can become impotent.39 It would be 
wrong to consider the feelings of the public or their 
fear about vaccines quality and safety as mere 
baseless ‘rumours’, ‘speculations’ or ‘illiteracy’, as 
many writers and health providers may call it,40 
when there is evidence that cause the public to 
question the safety and quality of some vaccines.41 
In such a situation, the stakeholders’ responsibility 
is to investigate into the cause of the matter, and if 
merit is found in it, then a step should be taken to 
prevent future occurrence. We have seen earlier,42 
that the “current laws and regulations for 
immunizations in the United States are the federal 
government’s direct response to public health crises, 
caused by unsafe vaccines in the 20th century.”43 The 
developing countries should therefore, also take a 
strong commitment to provide enforceable laws 
and regulations concerning clinical trials in 
particular, and immunization/vaccination in 
general. This would, undoubtedly, protect the 
people of developing countries from falling preys 
and victims in the hands of international 
pharmaceutical companies, who take the advantage 
of lack of enforceable legal framework for clinical 
trials and therefore, consider the developing 
countries as their affordable laboratories for 
testing the efficacy of their new drugs.44 
In the developed countries, clinical trials and 
vaccination generally, are governed by strong legal 
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and regulatory frameworks enforced by 
competent regulatory bodies;45 in charge of the 
regulation of pharmaceutical and biomedical 
sectors. In these countries, all clinical trials are 
subject to the approval and supervision of such 
bodies.46 This is the path the developing countries 
must follow so that their people will have 
confidence in them, and will accept any 
immunization programme or vaccination 
approved by the government as serving their best 
interest. 
 
3. Strengthening the Role of 
Regulatory Authorities of Developing 
Countries in Clinical Trials: Beyond Ethical 
Considerations 
 
A country that is serious about safety and 
health of its citizens would like to establish an 
independent regulatory agency, which shall be 
empowered by the law to ensure safety, quality 
and efficacy of all biological products, including 
vaccines, which are manufactured or intended to 
be used in the country. Such agency shall have 
power not only to approve or disapprove, but also 
monitor and follow up all the stages involved in 
the production of the products and or in carrying 
out clinical trials or studies for the efficacy, quality 
or safety of a vaccine or other biomedical 
products. 
The World Health Organization, through its 
Expert Committee on Biological Standardization, 
established some international standards of 
vaccine efficacy, safety and quality. These 
standards or guidelines are to help the WHO and 
the national regulatory authorities, in monitoring 
how a licensed vaccine meets the standards. The 
WHO encourages all countries to have a reliable 
and functioning regulatory authority.47 
For their understanding of the importance of 
having a functional and independent regulatory 
authority that would work to ensure that all 
vaccines used in their countries meet the 
international standards of efficacy, quality and 
safety, all the developed countries have 
established reliable and well-functioning vaccine 
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regulatory system.48 In each country, a competent 
regulatory authority is established and legally 
empowered to give authorization to use a 
biomedical drug, to start or to continue a clinical 
trial.49 
The situation in the developing countries is very 
poor. There are about only one quarter of the total 
countries with national regulatory authorities.50 As 
a result of lack of adequate and functioning 
legislation in this area, and because of the lower 
research cost for clinical trials, international 
pharmaceutical companies use that advantage to 
exploit the people of the developing countries51 
where they recruit them in testing their new 
products which would later be sold mainly to 
patients in the developed world.52 A recent study 
shows that all clinical trials sponsored by American 
pharmaceutical companies, the proportion of the 
trials conducted in the U.S have decreased from 
90% in 1999, to 47% in 2007. In Europe, the 
European Medicine Agency have estimated that 
quarter of the participants recruited for clinical 
trials for new drugs between 2005-2008, came 
from developing countries, particularly Africa.53 
There are international guidelines, set out to 
guide for the conduct of clinical trials involving 
human subjects, but these guidelines are mere 
voluntary ethical norms, which are generally non-
enforceable in law.54 Such guidelines include the 
Nuremberg Code, the Declaration of Helsinki, 
Article 7 of the International Covenant on Civil and 
Political Rights, the Council for International 
Organizations of Medical Sciences, and the 
International Council for Harmonization. 
To build and strengthen the capacity of the 
regulatory authorities in the developing countries, 
the WHO in 1997 launched an initiative for that 
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purpose. To achieve its objectives, the initiative 
undertakes a five step capacity development 
process, relevant to the requirements of each of 
the countries. These are: 
1) Defining and then regularly updating 
benchmarks and other tools used to access 
whether a national regulatory system is capable 
of ensuring that the vaccines used and/or made 
in its country have made the standards of quality, 
safety and efficacy. 
2) Using benchmark indicators and 
other pertinent tools to assess the national 
regulatory system. 
3) Working with the country’s 
regulators and other health officials in drawing 
up an institutional development plan for dealing 
with any shortcomings in the country’s 
regulatory system and for building upon the 
existing regulatory strengths in the country. 
4) Implementing the institutional 
development plan which may involve technical 
support or staff training, to perform regulatory 
functions. 
5) Re-assessing the national regulatory 
authority within two years to evaluate 
progress.55 
In 2004, the WHO launched the Developing 
Countries Vaccines Regulators Network, with the 
aim of strengthening the regulatory capacity of 
developing countries to be able to assess clinical 
trials proposals and to oversee ongoing clinical 
trials. The network allows member countries to 
share expertise and information, particularly 
information about problems of vaccine safety 
and efficacy which may have surfaced during a 
clinical trial.56 
Since the beginning of the WHO’s 
strengthening initiative in 1997, there have been 
record of increase of number of developing 
countries that have functional national 
regulatory authorities. Between 1997 to 2008, 
the number of the countries increased from 19% 
(37 out) of WHO’s 190 member States, to 30% 
(58) of WHO 193 member States.57 But even with 
this progress, the legislations in many of these 
countries are still not satisfactory as they do not 
assign a clear mandate for regulation and 
oversight of clinical trials to a specific body 
within the health authorities. With multiple and 
unclear scope of authority, such regulatory 
authorities would invariably be in conflict of 
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interest and each may assume that it lacks the 
necessary levers to take up the challenge of 
regulation.58 
 
4. Findings and Conclusion 
 
Despite the efforts of the WHO through its 
various initiatives to strengthen the capacity of 
national regulatory authorities for vaccine and 
immunization in developing countries, the desired 
success could not be achieved without the 
developing countries showing their commitment 
towards establishing functioning regulatory 
authorities, to secure the execution of activities, 
relevant to their functions in regulating clinical 
trials so as to guarantee the quality, efficacy and 
safety of vaccines, as well as to protect their 
citizens from being used as guinea pigs by 
pharmaceutical and research corporations. 
Clinical trials are necessary if new, safe and 
effective medicines are to be developed. However, 
as the multinational pharmaceutical companies 
and other research organizations continue to 
troop into developing countries -as a way of 
circumventing restrictive regulations in the 
developed countries- for conducting clinical trials, 
the national governments of these developing 
countries should not allow the pharmaceutical 
industry to go further in the direction it has 
already taken; where medical ethics, rules and 
human rights are sacrificed at the altar of 
profiteering. Ensuring the quality, safety and 
efficacy of vaccines used in immunization is a most 
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